## **ALARACT 227/2013**

## DTG: P 161525Z SEP 13

THIS MESSAGE HAS BEEN TRANSMITTED BY USAITA ON BEHALF OF //DASG-LOZ//

SUBJECT: GUIDANCE FOR COMMANDERS ON THE USE OF QUARANTINED ANTIDOTE TREATMENT NERVE AGENT AUTOINJECTOR (ATNAA)//

## (U) REFERENCES.

REF/A/AR 40-3, MEDICAL, DENTAL AND VETERINARY CARE/22 FEB 08//
REF/B/AR 40-61, MEDICAL LOGISTICS POLICIES/28 JAN 05//
REF/C/DA SUPPLY BULLETIN 8-75-S11/ 20 NOV 12//
REF/D/MMQC MESSAGE 13-1281/ANTIDOTE TREATMENT/MERIDIAN MEDICAL
TECHNOLOGIES (MMT)/01 APR 13//
REF/E/MMQC MESSAGE 13-1302/ANTIDOTE TREATMENT-NERVE AGENT/MERIDIAN
MEDICAL TECHNOLOGIES (MMT)//08 APR 13//
REF/F/ALARACT 090/2013 - GUIDANCE FOR COMMANDERS ON THE USE OF
QUARANTINED ANTIDOTE TREATMENT NERVE AGENT AUTOINJECTOR (ATNAA)

- 1. (U) SITUATION. THE PURPOSE OF THIS ALARACT IS TO PROVIDE CONTINUING GUIDANCE ON THE USE OF QUARANTINED ANTIDOTE TREATMENT NERVE AGENT AUTOINJECTOR (ATNAA), NSN 6505-01-362-7427. THIS MESSAGE APPLIES TO DEPLOYED SERVICE MEMBERS DEEMED AT RISK FOR CHEMICAL, BIOLOGICAL, RADIOLOGICAL, AND NUCLEAR (CBRN) ATTACK, ARMY MILITARY, DA CIVILIANS, AND CONTRACT PERSONNEL AT DEPOTS AND ARMY RESEARCH AND TRAINING FACILITIES THAT HAVE POTENTIAL FOR EXPOSURE TO NERVE AGENTS. THIS MESSAGE ALSO APPLIES TO ARMY FIRST RESPONDERS AT INSTALLATIONS AND HOMELAND DEFENSE FORCES RESPONDING TO A CBRN EVENT. IT IS IMPERATIVE THAT THESE ARMY PERSONNEL HAVE ACCESS TO APPROPRIATE NERVE AGENT TREATMENT. THE ATNAA MANUFACTURER, MERIDIAN MEDICAL TECHNOLOGIES (MMT), INC., REPORTED THAT A FRACTION OF THE CURRENT SUPPLY OF ATNAA DISTRIBUTED MAY NOT CONTAIN THE FULL AMOUNT OF ATROPINE OR THE FULL AMOUNT OF PRALIDOXIME CHLORIDE (2-PAM). IN THE VERY FEW CASES WHERE THERE IS NO 2-PAM IN THE AUTOINJECTOR, ARMY PERSONNEL WILL KNOW IMMEDIATELY IF THE AUTOINJECTOR IS DEFECTIVE AS THE ATNAA NEEDLE WILL NOT EXTEND. IN THE EVENT AN ARMY USER HAS A LOW FILL AUTOINJECTOR, THE NEEDLE WILL DEPLOY NORMALLY AND ANY RISK ASSOCIATED WITH THE LOW FILL IS CLINICALLY INSIGNIFICANT. IF SYMPTOMS PERSIST, ADMINISTER ADDITIONAL ATNAA ACCORDING TO DOCTRINE.
- 2. (U) MISSION. EFFECTIVE IMMEDIATELY, THE ARMY CONTINUES TO ISSUE ATNAA (NSN 6505-01-362-7427) TO ARMY PERSONEL IDENTIFIED IN PARA 1 ABOVE IN ORDER TO DEFEND AGAINST POTENTIAL CBRN EVENTS.

- 3. (U) EXECUTION.
- 3.A. (U) ARMY PERSONNEL ISSUED ATNAA (NSN 6505-01-362-7427) WILL CONTINUE TO USE ATNAA ACCORDING TO DOCTRINE. IF AN INDIVIDUAL ATNAA (NSN 6505-01-362-7427) FAILS TO IMMEDIATELY DISCHARGE, OR THE USER DOES NOT RECEIVE ADEQUATE MEDICAL BENEFIT WITH ADMINISTRATION OF ONE AUTOINJECTOR, THE USER/BUDDY WILL CONTINUE TO DOSE WITH THE REMAINING UNUSED AUTOINJECTORS FROM THE BASIC ISSUE OF THREE AUTOINJECTORS. REGARDLESS OF THE NUMBER OF AUTOINJECTORS USED, DEFINITIVE MEDICAL CARE SHOULD BE SOUGHT.
- 3.B. (U) UNITS MAY ISSUE ADDITIONAL ATNAA SUPPLIES TO THE UNIT MEDIC FOR DISTRIBUTION TO INDIVIDUALS TO REPLACE DEFECTIVE ATNAA AND TREAT CASUALTIES DURING A CBRN EVENT.
- 3.C. (U) ATNAA USE AND REMEDIATION IS BEING COORDINATED WITH THE FOOD AND DRUG ADMINISTRATION AND THE DEFENSE LOGISTICS AGENCY (DLA). ONCE REMEDIATED OR NEWLY MANUFACTURED PRODUCT IS AVAILABLE, UNUSED ATNAAS (NSN 6505-01-362-7427) WILL BE REPLENISHED ON A ONE-FOR-ONE BASIS. REPLENISHMENT WILL BE DETERMINED BY DISTRIBUTION RECORDS AND DESTRUCTION DOCUMENTS APPROVED BY ACCOUNTABILITY OFFICERS. THERE ARE CURRENTLY NO APPROVED REMEDIATION PROCEDURES FOR USE AT THE LOCAL LEVEL.
- 4. (U) SUSTAINMENT. UNITS WILL MAINTAIN ACCURATE DISTRIBUTION RECORDS AS TO QUANTITY AND LOT NUMBER ISSUED TO ENSURE ACCOUNTABILITY. INVENTORY CONTROL RECORDS ARE INCLUSIVE OF STORAGE, DISTRIBUTION, AND DISPOSITION MANAGEMENT OF ATNAA. THIS INFORMATION IS REQUIRED TO ASSIST WITH THE REMEDIATION AND REPLACEMENT OF PRODUCT. ON-HAND ATNAA THAT IS REACHING EXPIRATION DATE WILL BE TURNED IN IAW EXISTING SB 8-75-S7, MCDM POLICY. ALL ACTIVITIES WILL WORK WITH USAMMA TO REPLACE EXPIRING STOCK. EXISTING ON-HAND ATNAA ASSETS ARE ELIGIBLE FOR SHELF-LIFE EXTENSION PROGRAM (SLEP) TESTING AND EXTENSIONS.
- 5. (U) COMMAND AND SIGNAL.
- 5.A. (U) HQDA POCS:
- 5.A.1. (U) LTC MARLA J FERGUSON, MEDICAL COUNTERMEASURES SYSTEMS (MCS) COM: 301-619-8425, DSN: 343-8425, E-MAIL: MARLA.J.FERGUSON.MIL@MAIL.MIL
- 5.A.2. (U) DR. DAVID SMITH, MCS, COM: 301-619-8027, DSN: 343-8027, DAVID.J.SMITH222.CIV@MAIL.MIL

- 5.A.3. (U) MR. DAVID R. BRUNE, OTSG DIRECTORATE OF HEALTHCARE OPERATIONS, COM: 703-681-0952, DSN: 761-0952, DAVID.R.BRUNE.CIV@MAIL.MIL
- 5.A.4. (U) MAJ NIKKI L DAVIS, OTSG DIRECTORATE OF LOGISTICS, COM: 703-681-8074, DSN: 761-8074, NIKKI.L.DAVIS.MIL@MAIL.MIL
- 5.B. (U) THIS MESSAGE IS VALID UNTIL RESCENDED OR UNTIL ADDITIONAL GUIDANCE IS PROVIDED.
- 6. EXPIRATION DATE CANNOT BE DETERMINED